Biocon to merge Biocon Biologics in $5.5 billion deal
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Ipca Laboratories receives three observations from USFDA for API facility at Tarapur
This campaign is to raise awareness about the crucial role helmet usage plays in saving lives
Growing patent filings and tier-2 innovators reflect expanding national research base
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
The acquisitions merge DatCard and Sorna’s expertise in clinical data sharing with Avandra’s de-identified patient data aggregation platform
Here's a new ray of hope for new hope for patients suffering from Meniere’s disease (MD) and sensorineural hearing loss
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
Now a test that offers new precision in prostate cancer detection
Subscribe To Our Newsletter & Stay Updated